Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19

Hong Foo; Fiona Phan; Melissa Bagatella; Irene Petrovski; Vana Nagendra; Priya Acharya; Miriam Levy; Emilia Prakoso

doi:10.1007/s10096-023-04599-5

Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19

Hong Foo
, Fiona Phan
, Melissa Bagatella
, Irene Petrovski
, Vana Nagendra
, Priya Acharya
, Miriam Levy
, Emilia Prakoso

NSW Health Pathology
Liverpool Hospital
Campbelltown Hospital
University of New South Wales
The University of Sydney

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

Reactivation of hepatitis B (HBV) is a well-documented risk associated with certain immunosuppressive drugs. Baricitinib, a janus kinase inhibitor, and tocilizumab, an interleukin-6 (IL-6) receptor antagonist, are immunomodulatory drugs which have been used with systemic corticosteroids as short course treatment of patients with moderate to severe COVID-19.

Original language	English
Pages (from-to)	799-801
Number of pages	3
Journal	European Journal of Clinical Microbiology and Infectious Diseases
Volume	42
Issue number	6
DOIs	https://doi.org/10.1007/s10096-023-04599-5
Publication status	Published - Jun 2023
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1007/s10096-023-04599-5

Cite this

@article{490b837421ab4c7dadabb44b2afcbff2,

title = "Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19",

abstract = "Reactivation of hepatitis B (HBV) is a well-documented risk associated with certain immunosuppressive drugs. Baricitinib, a janus kinase inhibitor, and tocilizumab, an interleukin-6 (IL-6) receptor antagonist, are immunomodulatory drugs which have been used with systemic corticosteroids as short course treatment of patients with moderate to severe COVID-19.",

author = "Hong Foo and Fiona Phan and Melissa Bagatella and Irene Petrovski and Vana Nagendra and Priya Acharya and Miriam Levy and Emilia Prakoso",

year = "2023",

month = jun,

doi = "10.1007/s10096-023-04599-5",

language = "English",

volume = "42",

pages = "799--801",

journal = "European Journal of Clinical Microbiology and Infectious Diseases",

issn = "0934-9723",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "6",

}

TY - JOUR

T1 - Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19

AU - Foo, Hong

AU - Phan, Fiona

AU - Bagatella, Melissa

AU - Petrovski, Irene

AU - Nagendra, Vana

AU - Acharya, Priya

AU - Levy, Miriam

AU - Prakoso, Emilia

PY - 2023/6

Y1 - 2023/6

N2 - Reactivation of hepatitis B (HBV) is a well-documented risk associated with certain immunosuppressive drugs. Baricitinib, a janus kinase inhibitor, and tocilizumab, an interleukin-6 (IL-6) receptor antagonist, are immunomodulatory drugs which have been used with systemic corticosteroids as short course treatment of patients with moderate to severe COVID-19.

AB - Reactivation of hepatitis B (HBV) is a well-documented risk associated with certain immunosuppressive drugs. Baricitinib, a janus kinase inhibitor, and tocilizumab, an interleukin-6 (IL-6) receptor antagonist, are immunomodulatory drugs which have been used with systemic corticosteroids as short course treatment of patients with moderate to severe COVID-19.

UR - https://www.scopus.com/pages/publications/85153032003

UR - https://go.openathens.net/redirector/westernsydney.edu.au?url=https://doi.org/10.1007/s10096-023-04599-5

U2 - 10.1007/s10096-023-04599-5

DO - 10.1007/s10096-023-04599-5

M3 - Article

C2 - 37084117

AN - SCOPUS:85153032003

SN - 0934-9723

VL - 42

SP - 799

EP - 801

JO - European Journal of Clinical Microbiology and Infectious Diseases

JF - European Journal of Clinical Microbiology and Infectious Diseases

IS - 6

ER -

Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this